Landry Nfonsam

Landry Nfonsam

Auto-generated profile, based on publicly available information

Landry Nfonsam

Molecular Genetics Laboratory, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences Hamilton Ontario Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Human Mutation
Verified
Journal Article
Open access
PDF file
Petros KountourisPetros Kountouris
Petros Kountouris
CSCoralea Stephanou
Coralea Stephanou
Carsten Werner LedererCarsten Werner Lederer
Carsten Werner Lederer
JTJan Traeger-Synodinos
Jan Traeger-Synodinos
CBCeleste Bento
Celeste Bento
CPClinGen Hemoglobinopathy Variant Curation Expert Panel
ClinGen Hemoglobinopathy Variant Curation Expert Panel
Accurate and consistent interpretation of sequence variants is integral to the delivery of safe and reliable diagnostic genetic services. To standardize the interpretation process, in 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published a joint guideline based on a set of shared standards for the classification of variants in Mendelian diseases. The generality of these standards and their subjective interpretation between laboratories has prompted efforts to reduce discordance of variant classifications, with focus on the expert specification of the ACMG/AMP guidelines for individual genes or diseases. Herein, we describe our experience as a ClinGen Variant Curation Expert Panel (VCEP) to adapt the ACMG/AMP criteria for the classification of variants in three globin genes (HBB, HBA2, HBA1) related to recessively inherited hemoglobinopathies, including five evidence categories, as use cases demonstrating the process of specification and the underlying rationale.

1 May 2019 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
HDHussein Daoud
Hussein Daoud
MGMahdi Ghani
Mahdi Ghani
LNLandry Nfonsam
Landry Nfonsam
RPRyan Potter
Ryan Potter
SOShelley Ordorica
Shelley Ordorica
OJOlga Jarinova
Olga Jarinova

21 September 2018 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
LNLandry Nfonsam
Landry Nfonsam
SOShelley Ordorica
Shelley Ordorica
MGMahdi Ghani
Mahdi Ghani
RPRyan Potter
Ryan Potter
ASAudrey Schaffer
Audrey Schaffer
LBLucas Bronicki
Lucas Bronicki
Background: Advances in molecular technologies and in-silico variant prediction tools offer wide-ranging opportunities in diagnostic settings, yet they also present with significant limitations. Objective: Here, we contextualise the limitations of next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA) and in-silico prediction tools routinely used by diagnostic laboratories by reviewing specific experiences from our diagnostic laboratory. Methods: We investigated discordant annotations and/or incorrect variant ‘callings’ in exons of 56 genes constituting our cardiomyopathy and connective tissue disorder NGS panels. Discordant variants and segmental duplications (SD) were queried using the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool and the University of California Santa Cruz genome browser, respectively, to identify regions of high homology. Discrepant variant analyses by in-silico models were re-evaluated using updated file entries. Results: We observed a 5% error rate in MYH7 variant ‘calling’ using MLPA, which resulted from >90% homology of the MYH7 probe-binding site to MYH6. SDs were detected in TTN, PKP2 and MYLK. SDs in MYLK presented the highest risk (15.7%) of incorrect variant ‘calling’. The inaccurate ‘callings’ and discrepant in-silico predictions were resolved following detailed investigation into the source of error. Conclusion: Recognising the limitations described here may help avoid incorrect diagnoses and leverage the power of new molecular technologies in diagnostic settings.

30 September 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
LNLandry Nfonsam
Landry Nfonsam
LHLijia Huang
Lijia Huang
NCNancy Carson
Nancy Carson
JMJean McGowan‐Jordan
Jean McGowan‐Jordan
MBMelanie Beaulieu Bergeron
Melanie Beaulieu Bergeron
OJOlga Jarinova
Olga Jarinova
Background: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy (LVH) in the absence of predisposing cardiovascular conditions. Pathogenic variants in at least 16 cardiac sarcomeric genes have been implicated in HCM, most of which act in a dominant‐negative fashion. However loss‐of‐function (haploinsufficiency) is the most common disease mechanism for pathogenic variants in MYBPC3, suggesting that MYBPC3 complete deletion may play a role in HCM pathogenesis. Here, we investigate MYBPC3 complete deletion as a disease mechanism in HCM by analyzing two unrelated patients with confirmed diagnosis of HCM that tested negative by Sanger sequencing analysis.Methods: MYBPC3 complete deletion was investigated by Multiplex ligation‐dependent probe amplification (MLPA) and microarray analyses. The mechanism of deletion was investigated by interrogating the SINEBase database.Results: Patient‐1 was diagnosed with nonobstructive HCM in his mid‐40s while undergoing assessment for palpitations, and patient‐2 with obstructive HCM in his late‐20s while undergoing systolic heart murmur assessment for an unrelated illness. MLPA testing revealed a heterozygous deletion of all MYBPC3 exons in both patients. Subsequent microarray testing confirmed these deletions which extended beyond the 5′ and 3′ ends of MYBPC3. Genomic assessment suggested that these deletions resulted from Alu/Alu‐homologous recombination.Conclusion: Our results demonstrate that haploinsufficiency resulting from MYBPC3 complete deletion, potentially mediated by Alu recombination, is an important disease mechanism in cardiomyopathy and emphasizes the importance of copy number variation analysis in patients clinically suspected of HCM.

1 April 2021 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
LLLeichelle Little
Leichelle Little
GEGrace Ediae
Grace Ediae
LNLandry Nfonsam
Landry Nfonsam
MGMahdi Ghani
Mahdi Ghani
JRJulie Richer
Julie Richer
LBLucas Bronicki
Lucas Bronicki

1 November 2026 in medRxiv
Verified
Preprint
Open access
CSCoralea Stephanou
Coralea Stephanou
IFIrene Fylaktou
Irene Fylaktou
HHHashim Halim-Fikri
Hashim Halim-Fikri
TKTamara T Koopmann
Tamara T Koopmann
LNLandry E Nfonsam
Landry E Nfonsam
CPClinGen Hemoglobinopathy Variant Curation Expert Panel
ClinGen Hemoglobinopathy Variant Curation Expert Panel
Background: The ClinGen Hemoglobinopathy Variant Curation Expert Panel (VCEP) was established in 2019 to develop disease-specific adaptations of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) sequence variant interpretation framework for hemoglobinopathies. This study describes the development, validation, and ClinGen approval of the first disease-specific ACMG/AMP specifications for autosomal recessive thalassemia related to HBB and HBA2, providing a standardized framework for globin gene variant interpretation. Methods: Disease-specific ACMG/AMP rule specifications were developed in accordance with ClinGen procedures and Variant Classification Working Group recommendations and evaluated through pilot curation of representative HBB and HBA2 variants using the ClinGen Variant Curation Interface (VCI), with independent biocurator assessment, expert review, and consensus approval. Results: A total of 34 disease-specific evidence specifications were developed across the two gene-disease pairs, encompassing 22 ACMG/AMP evidence criteria and one modification to the ACMG/AMP evidence-combining rules. Pilot application to 33 representative variants (20 HBB, 13 HBA2) demonstrated high concordance with established pathogenic and benign classifications while providing a standardized framework for resolving variants with conflicting or limited evidence. Following pilot validation, the specifications received ClinGen approval, and all curated variants with supporting evidence were disseminated through the ClinGen Evidence Repository (ERepo) and ClinVar. Conclusions: The ClinGen Hemoglobinopathy VCEP specifications provide the first ClinGen-approved disease-specific ACMG/AMP rule specifications for HBB and HBA2 variants related to thalassemia. These specifications establish a robust and transparent framework for harmonized globin variant interpretation and provide a foundation for sustained expert curation, continued refinement through emerging evidence, and expansion to additional hemoglobinopathy gene-disease pairs.